ERAS Stock Summary and Trading Ideas (Erasca | NASDAQ:ERAS)

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca trades on the NASDAQ stock market under the symbol ERAS.

As of February 9, 2026, ERAS stock price declined to $12.01 with 2,504,390 million shares trading.

ERAS has a beta of 2.19, meaning it tends to be more sensitive to market movements. ERAS has a correlation of 0.14 to the broad based SPY ETF.

ERAS has a market cap of $3.72 billion. This is considered a Mid Cap stock.

In the last 3 years, ERAS traded as high as $12.48 and as low as $1.01.

The top ETF exchange traded funds that ERAS belongs to (by Net Assets): IWM, VTI, XBI, IWN, IBB.

ERAS has outperformed the market in the last year with a price return of +655.3% while the SPY ETF gained +16.7%. ERAS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +429.1% and +25.0%, respectively, while the SPY returned +3.7% and +0.2%, respectively.

ERAS support price is $11.44 and resistance is $13.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ERAS shares will trade within this expected range on the day.